JAK/TYK2
2 years 5 months ago
Upadacitinib shows promising response in the treatment of nr-AxSpA in the SELECT-AXIS 2 study. Deodhar et al showed the ASAS40 response rate for UPA was twice vs placebo (45% vs 23%). 12/14 of the secondary endpoints were also met #EULAR2022 @RheumNow OP0016 https://t.co/dOWVJdLRtG
Are Tyk2 inhibitors JAK inhibitors?
Yes, no, maybe
Answer
Tyrosine kinase 2 (TYK2) is a member of the JAK kinase family. These molecules regulate signal transduction downstream of receptors for…
One area of continued interest for many rheumatologists is the field of non-radiographic axial spondyloarthritis. Furthermore, the question of the utility of JAK inhibitors for the treatment of axial…
At EULAR 2022, I look forward to key topics and presentations in psoriatic arthritis (PsA). I will be sharing the details of these studies once they are presented.
There are new therapies that…
2 years 5 months ago
Have always been fascinated by the idea that some b/tsDMARDs might have effects on pain and fatigue beyond inflammation control.
Baricitinib data in RA before, & now this from guselkumab. Substantial effect on pain beyond SJC/CRP attributable?
POS1030 #EULAR2022 #IL23 @RheumNow https://t.co/fxqIGnlkwU
2 years 5 months ago
SELECT-AXIS 2: RCT UPA 15 mgQD vs. PBO in NRAxSpA
as expected:
↘️disease activity
↘️pain and function
↘️QoL
at 14 wks
no new safety alerts https://t.co/2efpx7Mi6i
Poster Hall